Alparslan Serarslan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alparslan Serarslan has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
Deniz Meydan
Department of Radiation Oncology, Faculty of Medicine, Ondokuz Mayıs University
9 shared publicationsBilge Gürsel
Department of Radiation Oncology, Faculty of Medicine, Ondokuz Mayıs University
6 shared publications- Bilge Gursel
Department of Radiation Oncology, Faculty of Medicine, Ondokuz Mayıs University, Samsun 55270, Turkey
5 shared publications Nilgün Özbek Okumuş
Department of Radiation Oncology, Faculty of Medicine, Ondokuz Mayıs University
5 shared publications- Nilgun Ozbek Okumus
Department of Radiation Oncology, Ondokuz Mayıs University Faculty of Medicine, Samsun, Turkey
4 shared publications Nilgun Ozbek Okumus
3 shared publications
Latest Publications
- Open Access
- 5 August 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1901196
Dual optimization in single-isocenter radiosurgery for multiple brain metastases: a dosimetric planning study
Background: This study evaluated a dual-optimization strategy for single-isocenter multiple-target stereotactic radiosurgery (SIMT-SRS) in patients with multiple brain metastases, combining target-anchored isocenter placement with individualized dose prescription for each planning target volume (PTV). Methods: Three volumetric modulated arc therapy-based SIMT-SRS planning techniques were compared in 22 patients harboring 5–10 brain metastases: geometric center isocenter with composite dose prescription (GCI-Comp), target-anchored isocenter with composite dose prescription (TAI-Comp), and target-anchored isocenter with individual dose prescription (TAI-Ind). Dosimetric parameters for PTVs and organs at risk (OARs) were extracted and compared using the Friedman test followed by Bonferroni-corrected post hoc analyses. Results: All three techniques achieved equivalent target coverage (V95% > 99%, p = 0.202), plan quality (Q RTOG , p = 0.385), and conformity (CI Paddick , p = 0.546). Compared to GCI-Comp and TAI-Comp, TAI-Ind produced significantly higher intratumoral dose escalation (PTV–D max : 2025.60 vs. 2113.80 vs. 2241.34 cGy, p < 0.001) while achieving a significantly steeper dose gradient (R 50% : 13.43 vs. 12.07 vs. 10.31; GI Paddick : 12.91 vs. 12.10 vs. 9.41; both p < 0.001). TAI-Ind also resulted in the lowest normal brain dose exposure (V12Gy: 35.53 cm 3 ; D 50% : 322.36 cGy) and significantly reduced maximum doses to the hippocampus, brainstem, spinal canal, and bilateral cochleae (all p < 0.001). These dosimetric advantages were achieved at the expense of requiring a higher number of monitor units (6013.84 vs. 6494.89 vs. 7268.92, p < 0.001). Conclusions: The TAI-Ind dual-optimization strategy provided greater intratumoral dose escalation and more favorable OARs sparing compared with the composite-prescription techniques, without compromising target coverage. This approach represents a promising strategy for SIMT-SRS planning in patients with multiple brain metastases, warranting further clinical validation.
- 5 August 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1901196
Open AccessDual optimization in single-isocenter radiosurgery for multiple brain metastases: a dosimetric planning study
Background: This study evaluated a dual-optimization strategy for single-isocenter multiple-target stereotactic radiosurgery (SIMT-SRS) in patients with multiple brain metastases, combining target-anchored isocenter placement with individualized dose prescription for each planning target volume (PTV). Methods: Three volumetric modulated arc therapy-based SIMT-SRS planning techniques were compared in 22 patients harboring 5–10 brain metastases: geometric center isocenter with composite dose prescription (GCI-Comp), target-anchored isocenter with composite dose prescription (TAI-Comp), and target-anchored isocenter with individual dose prescription (TAI-Ind). Dosimetric parameters for PTVs and organs at risk (OARs) were extracted and compared using the Friedman test followed by Bonferroni-corrected post hoc analyses. Results: All three techniques achieved equivalent target coverage (V95% > 99%, p = 0.202), plan quality (Q RTOG , p = 0.385), and conformity (CI Paddick , p = 0.546). Compared to GCI-Comp and TAI-Comp, TAI-Ind produced significantly higher intratumoral dose escalation (PTV–D max : 2025.60 vs. 2113.80 vs. 2241.34 cGy, p < 0.001) while achieving a significantly steeper dose gradient (R 50% : 13.43 vs. 12.07 vs. 10.31; GI Paddick : 12.91 vs. 12.10 vs. 9.41; both p < 0.001). TAI-Ind also resulted in the lowest normal brain dose exposure (V12Gy: 35.53 cm 3 ; D 50% : 322.36 cGy) and significantly reduced maximum doses to the hippocampus, brainstem, spinal canal, and bilateral cochleae (all p < 0.001). These dosimetric advantages were achieved at the expense of requiring a higher number of monitor units (6013.84 vs. 6494.89 vs. 7268.92, p < 0.001). Conclusions: The TAI-Ind dual-optimization strategy provided greater intratumoral dose escalation and more favorable OARs sparing compared with the composite-prescription techniques, without compromising target coverage. This approach represents a promising strategy for SIMT-SRS planning in patients with multiple brain metastases, warranting further clinical validation.
- Open Access
- 26 February 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1786400
Gynecologic radiation oncology practice: retrospective analysis of a tertiary radiotherapy referral center
Background: This study aimed to characterize gynecologic cancers in radiation oncology practice and compare survival outcomes with those reported in countries exhibiting a high or very high human development index. Methods: A retrospective review was conducted involving the medical records of all patients (n = 11,720) treated at our radiotherapy center between January 2012 and December 2022. Of these, 911 women with gynecologic cancers who underwent treatment and follow-up at our center were included in the analysis. Demographic, disease-related, and treatment-related characteristics, as well as relapse patterns and survival outcomes, were recorded and analyzed. Results: Gynecologic cancers (30%) ranked second among malignancies of women in radiation oncology, after breast cancer (35%). The two most common gynecologic cancers among all female malignancies in radiation oncology were corpus uteri cancer (20%, rank second after breast cancer) and cervical cancer (9%, rank third). With the exception of ovarian cancer, most gynecologic cancers were referred for radiotherapy at FIGO stages I–II (75%, n = 680). Curative and adjuvant radiotherapy rates were 95% (n = 771) and 75% (n = 580), respectively. The most frequently administered radiotherapy technique was external beam radiotherapy combined with brachytherapy (53%, n = 419). The rate of brachytherapy application in gynecologic radiation oncology was 82%. Palliative radiotherapy was most commonly administered for ovarian cancer (57%) in gynecologic oncology. The primary indication for palliative RT was pain management (42%). Relapse predominantly occurred as distant metastases in corpus uteri and cervical cancers, whereas other gynecologic cancers commonly exhibited locoregional disease. Survival outcomes, except for vaginal cancer, were comparable to those reported in the literature. Conclusions: Gynecologic cancers constitute a substantial proportion of radiation oncology practice in women. Survival outcomes at our center largely align with those observed in countries exhibiting a high or very high human development index.
- 26 February 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1786400
Open AccessGynecologic radiation oncology practice: retrospective analysis of a tertiary radiotherapy referral center
Background: This study aimed to characterize gynecologic cancers in radiation oncology practice and compare survival outcomes with those reported in countries exhibiting a high or very high human development index. Methods: A retrospective review was conducted involving the medical records of all patients (n = 11,720) treated at our radiotherapy center between January 2012 and December 2022. Of these, 911 women with gynecologic cancers who underwent treatment and follow-up at our center were included in the analysis. Demographic, disease-related, and treatment-related characteristics, as well as relapse patterns and survival outcomes, were recorded and analyzed. Results: Gynecologic cancers (30%) ranked second among malignancies of women in radiation oncology, after breast cancer (35%). The two most common gynecologic cancers among all female malignancies in radiation oncology were corpus uteri cancer (20%, rank second after breast cancer) and cervical cancer (9%, rank third). With the exception of ovarian cancer, most gynecologic cancers were referred for radiotherapy at FIGO stages I–II (75%, n = 680). Curative and adjuvant radiotherapy rates were 95% (n = 771) and 75% (n = 580), respectively. The most frequently administered radiotherapy technique was external beam radiotherapy combined with brachytherapy (53%, n = 419). The rate of brachytherapy application in gynecologic radiation oncology was 82%. Palliative radiotherapy was most commonly administered for ovarian cancer (57%) in gynecologic oncology. The primary indication for palliative RT was pain management (42%). Relapse predominantly occurred as distant metastases in corpus uteri and cervical cancers, whereas other gynecologic cancers commonly exhibited locoregional disease. Survival outcomes, except for vaginal cancer, were comparable to those reported in the literature. Conclusions: Gynecologic cancers constitute a substantial proportion of radiation oncology practice in women. Survival outcomes at our center largely align with those observed in countries exhibiting a high or very high human development index.
Comparative miRNA Expression Profiling Reveals Candidates Involved in Prostate Cancer Radioresistance
Prostate cancer is the most common malignancy among men worldwide, and treatment response depends on tumor radiosensitivity. Micrornas (mirnas) are key regulators of cell proliferation, apoptosis, and dna damage response, and have been implicated in therapy resistance. However, their roles in prostate cancer radioresponse remain incompletely understood. This study investigated the expression patterns of ten selected mirnas associated with radiation resistance in other cancers in prostate cancer models. Radiation‐resistant pc‐3, radiation‐sensitive lncap, and normal prostate epithelial (hprec) cells were exposed to 0, 2, 4, 6, and 8 gy of ionizing radiation. Mirna expression levels were analyzed by quantitative pcr using snord48 as an internal control and calculated with the 2 − δδct method. In pc‐3 cells, mir‐20a‐5p, mir‐128‐3p, and mir‐135b‐5p showed significant dose‐dependent upregulation, whereas mir‐23b‐3p and mir‐381‐3p were downregulated. Mir‐128‐3p correlated positively with radiation dose, while mir‐23b‐3p and mir‐381‐3p showed negative correlations. Lncap cells exhibited moderate, non–dose‐dependent mirna changes. Distinct mirna signatures differentiate radiation‐resistant and radiation‐sensitive prostate cancer cells. Mir‐20a‐5p, mir‐128‐3p, and mir‐135b‐5p may contribute to radioresistance, whereas mir‐23b‐3p and mir‐381‐3p may act as radiosensitizers.
Comparative miRNA Expression Profiling Reveals Candidates Involved in Prostate Cancer Radioresistance
Prostate cancer is the most common malignancy among men worldwide, and treatment response depends on tumor radiosensitivity. Micrornas (mirnas) are key regulators of cell proliferation, apoptosis, and dna damage response, and have been implicated in therapy resistance. However, their roles in prostate cancer radioresponse remain incompletely understood. This study investigated the expression patterns of ten selected mirnas associated with radiation resistance in other cancers in prostate cancer models. Radiation‐resistant pc‐3, radiation‐sensitive lncap, and normal prostate epithelial (hprec) cells were exposed to 0, 2, 4, 6, and 8 gy of ionizing radiation. Mirna expression levels were analyzed by quantitative pcr using snord48 as an internal control and calculated with the 2 − δδct method. In pc‐3 cells, mir‐20a‐5p, mir‐128‐3p, and mir‐135b‐5p showed significant dose‐dependent upregulation, whereas mir‐23b‐3p and mir‐381‐3p were downregulated. Mir‐128‐3p correlated positively with radiation dose, while mir‐23b‐3p and mir‐381‐3p showed negative correlations. Lncap cells exhibited moderate, non–dose‐dependent mirna changes. Distinct mirna signatures differentiate radiation‐resistant and radiation‐sensitive prostate cancer cells. Mir‐20a‐5p, mir‐128‐3p, and mir‐135b‐5p may contribute to radioresistance, whereas mir‐23b‐3p and mir‐381‐3p may act as radiosensitizers.
- 1 January 2024
- Published by LookUs Bilisim A.S. in Turkish Journal of Oncology
- Vol. 39 (2) , 183-190
Radiotherapy with a Carboplatin/Paclitaxel Regimen in Patients with Non-Small-Cell Lung Cancer: Experience at Ondokuz Mayıs University
- 1 January 2024
- Published by LookUs Bilisim A.S. in Turkish Journal of Oncology
- Vol. 39 (2) , 183-190
Radiotherapy with a Carboplatin/Paclitaxel Regimen in Patients with Non-Small-Cell Lung Cancer: Experience at Ondokuz Mayıs University
- 1 January 2024
- Published by LookUs Bilisim A.S. in Turkish Journal of Oncology
- Vol. 39 (2) , 167-175
Normal Tissue Objective Tool in Radiotherapy Planning for Endometrial Cancer: A Dosimetric Study
- 1 January 2024
- Published by LookUs Bilisim A.S. in Turkish Journal of Oncology
- Vol. 39 (2) , 167-175
Normal Tissue Objective Tool in Radiotherapy Planning for Endometrial Cancer: A Dosimetric Study
- Open Access
- 6 June 2023
- Published by Springer Nature in BMC Cancer
- Vol. 23 (1) , 1-9
Ninety-degree angled collimator: a dosimetric study related to dynamic intensity-modulated radiotherapy in patients with endometrial carcinoma
Background: Our purpose was to ensure that the dose constraints of the organs at risk (OARs) were not exceeded while increasing the prescription dose to the planning target volume (PTV) from 45 to 50.4 Gray (Gy) with the dynamic intensity-modulated radiotherapy (IMRT) technique. While trying for this purpose, a new dynamic IMRT technique named 90° angled collimated dynamic IMRT (A-IMRT) planning was developed by us. Methods: This study was based on the computed tomography data sets of 20 patients with postoperatively diagnosed International Federation of Gynecology and Obstetrics stage 2 endometrial carcinoma. For each patient, conventional dynamic IMRT (C-IMRT, collimator angle of 0° at all gantry angles), A-IMRT (collimator angle of 90° at gantry angles of 110°, 180°, 215°, and 285°), and volumetric modulated arc therapy (VMAT) were planned. Planning techniques were compared with parameters used to evaluate PTV and OARs via dose-volume-histogram analysis using the paired two-tailed Wilcoxon’s signed-rank test; p < 0.05 was considered indicative of statistical significance. Results: All plans achieved adequate dose coverage for PTV. Although the technique with the lowest mean conformality index was A-IMRT (0.76 ± 0.05) compared to both C-IMRT (0.79 ± 0.04, p = 0.000) and VMAT (0.83 ± 0.03, p = 0.000), it protected the OARs especially the bladder (V45 = 32.84 ± 2.03 vs. 44.21 ± 6.67, p = 0.000), rectum (V30 = 56.18 ± 2.05 vs. 73.80 ± 4.75, p = 0.000) and both femoral heads (V30 for right = 12.19 ± 1.34 vs. 21.42 ± 4.03, p = 0.000 and V30 for left = 12.58 ± 1.48 vs. 21.35 ± 4.16, p = 0.000) better than C-IMRT. While the dose constraints of the bladder, rectum and bilateral femoral heads were not exceeded in any patient with A-IMRT or VMAT, they were exceeded in 19 (95%), 20 (100%) and 20 (100%) patients with C-IMRT, respectively. Conclusions: OARs are better protected when external beam radiotherapy is applied to the pelvis at a dose of 50.4 Gy by turning the collimator angle to 90° at some gantry angles with the dynamic IMRT technique in the absence of VMAT.
- 6 June 2023
- Published by Springer Nature in BMC Cancer
- Vol. 23 (1) , 1-9
Open AccessNinety-degree angled collimator: a dosimetric study related to dynamic intensity-modulated radiotherapy in patients with endometrial carcinoma
Background: Our purpose was to ensure that the dose constraints of the organs at risk (OARs) were not exceeded while increasing the prescription dose to the planning target volume (PTV) from 45 to 50.4 Gray (Gy) with the dynamic intensity-modulated radiotherapy (IMRT) technique. While trying for this purpose, a new dynamic IMRT technique named 90° angled collimated dynamic IMRT (A-IMRT) planning was developed by us. Methods: This study was based on the computed tomography data sets of 20 patients with postoperatively diagnosed International Federation of Gynecology and Obstetrics stage 2 endometrial carcinoma. For each patient, conventional dynamic IMRT (C-IMRT, collimator angle of 0° at all gantry angles), A-IMRT (collimator angle of 90° at gantry angles of 110°, 180°, 215°, and 285°), and volumetric modulated arc therapy (VMAT) were planned. Planning techniques were compared with parameters used to evaluate PTV and OARs via dose-volume-histogram analysis using the paired two-tailed Wilcoxon’s signed-rank test; p < 0.05 was considered indicative of statistical significance. Results: All plans achieved adequate dose coverage for PTV. Although the technique with the lowest mean conformality index was A-IMRT (0.76 ± 0.05) compared to both C-IMRT (0.79 ± 0.04, p = 0.000) and VMAT (0.83 ± 0.03, p = 0.000), it protected the OARs especially the bladder (V45 = 32.84 ± 2.03 vs. 44.21 ± 6.67, p = 0.000), rectum (V30 = 56.18 ± 2.05 vs. 73.80 ± 4.75, p = 0.000) and both femoral heads (V30 for right = 12.19 ± 1.34 vs. 21.42 ± 4.03, p = 0.000 and V30 for left = 12.58 ± 1.48 vs. 21.35 ± 4.16, p = 0.000) better than C-IMRT. While the dose constraints of the bladder, rectum and bilateral femoral heads were not exceeded in any patient with A-IMRT or VMAT, they were exceeded in 19 (95%), 20 (100%) and 20 (100%) patients with C-IMRT, respectively. Conclusions: OARs are better protected when external beam radiotherapy is applied to the pelvis at a dose of 50.4 Gy by turning the collimator angle to 90° at some gantry angles with the dynamic IMRT technique in the absence of VMAT.
- Open Access
- 1 March 2023
- Published by Springer Nature in Research Square
Ninety-degree angled collimator: a dosimetric study related to dynamic intensity-modulated radiotherapy in patients with endometrial carcinoma
Background Our purpose was to ensure that the dose constraints of the organs at risk (OARs) were not exceeded while increasing the prescription dose to the planning target volume (PTV) from 45 Gy to 50.4 Gy with the dynamic intensity-modulated radiotherapy (IMRT) technique. While trying for this purpose, a new dynamic IMRT technique that named 90° angled collimated dynamic IMRT (A-IMRT) planning was developed by us. Methods This study was based on the computed tomography data sets of 20 patients with postoperatively diagnosed International Federation of Gynecology and Obstetrics stage 2 endometrial carcinoma. For each patient, conventional dynamic IMRT (C-IMRT, collimator angle of 0° at all gantry angles), A-IMRT (collimator angle of 90° at gantry angles of 110°, 180°, 215°, and 285°), and volumetric modulated arc therapy (VMAT) were planned. Planning techniques were compared with parameters used to evaluate PTV and OARs via dose-volume-histogram analysis using the paired two-tailed Wilcoxon’s signed-rank test;p< 0.05 was considered indicative of statistical significance. Results All plans achieved adequate dose coverage for PTV. Conformality was best obtained with VMAT, whereas homogeneity was best obtained with C-IMRT. The conformality of A-IMRT was inferior to the conformality of C-IMRT; A-IMRT had similar homogeneity to VMAT. The bone marrow dose constraint was exceeded in 4 (20%), 16 (80%), and 18 (90%) patients with VMAT, A-IMRT, and C-IMRT, respectively. The bladder dose constraint was exceeded in no patients with A-IMRT or VMAT, but it was exceeded in 19 (95%) patients with C-IMRT. Dose constraints of the rectum and bilateral femoral heads were exceeded in no patients with A-IMRT or VMAT, but they were exceeded in 20 (100%) patients with C-IMRT. The dose constraint of the bowel (for V40 as in the RTOG 0418 trial) was exceeded in 4 (20%), 5 (25%), and 8 (40%) patients with VMAT, A-IMRT, and C-IMRT, respectively. Conclusions OARs are better protected when external beam radiotherapy is applied to the pelvis at a dose of 50.4 Gy by turning the collimator angle to 90° at some gantry angles with the dynamic IMRT technique in the absence of VMAT.
- 1 March 2023
- Published by Springer Nature in Research Square
Open AccessNinety-degree angled collimator: a dosimetric study related to dynamic intensity-modulated radiotherapy in patients with endometrial carcinoma
Background Our purpose was to ensure that the dose constraints of the organs at risk (OARs) were not exceeded while increasing the prescription dose to the planning target volume (PTV) from 45 Gy to 50.4 Gy with the dynamic intensity-modulated radiotherapy (IMRT) technique. While trying for this purpose, a new dynamic IMRT technique that named 90° angled collimated dynamic IMRT (A-IMRT) planning was developed by us. Methods This study was based on the computed tomography data sets of 20 patients with postoperatively diagnosed International Federation of Gynecology and Obstetrics stage 2 endometrial carcinoma. For each patient, conventional dynamic IMRT (C-IMRT, collimator angle of 0° at all gantry angles), A-IMRT (collimator angle of 90° at gantry angles of 110°, 180°, 215°, and 285°), and volumetric modulated arc therapy (VMAT) were planned. Planning techniques were compared with parameters used to evaluate PTV and OARs via dose-volume-histogram analysis using the paired two-tailed Wilcoxon’s signed-rank test;p< 0.05 was considered indicative of statistical significance. Results All plans achieved adequate dose coverage for PTV. Conformality was best obtained with VMAT, whereas homogeneity was best obtained with C-IMRT. The conformality of A-IMRT was inferior to the conformality of C-IMRT; A-IMRT had similar homogeneity to VMAT. The bone marrow dose constraint was exceeded in 4 (20%), 16 (80%), and 18 (90%) patients with VMAT, A-IMRT, and C-IMRT, respectively. The bladder dose constraint was exceeded in no patients with A-IMRT or VMAT, but it was exceeded in 19 (95%) patients with C-IMRT. Dose constraints of the rectum and bilateral femoral heads were exceeded in no patients with A-IMRT or VMAT, but they were exceeded in 20 (100%) patients with C-IMRT. The dose constraint of the bowel (for V40 as in the RTOG 0418 trial) was exceeded in 4 (20%), 5 (25%), and 8 (40%) patients with VMAT, A-IMRT, and C-IMRT, respectively. Conclusions OARs are better protected when external beam radiotherapy is applied to the pelvis at a dose of 50.4 Gy by turning the collimator angle to 90° at some gantry angles with the dynamic IMRT technique in the absence of VMAT.
- 6 July 2022
- Published by Taylor & Francis in Nutrition and Cancer
- Vol. 74 (10) , 1-10
Evaluation of Nutritional Status and Anxiety Levels in Patients Applying to the Radiation Oncology Outpatient Clinic during the COVID-19 Pandemic: Turkish Society for Radiation Oncology Group Study (TROD 12:02)
Cancer patients often face malnutrition, which negatively affects their response to cancer treatment. This study aims to analyze the effects of the COVID-19 pandemic on nutritional status and anxiety in cancer patients with different types and stages of cancer. This is a cross-sectional cohort study that includes 1,252 patients with varying cancer types from 17 radiation oncology centers. The nutritional risk scores (NRS-2002) and coronavirus anxiety scale (CAS) scores of all patients were measured. NRS-2002 ≥ 3 and CAS ≥ 5 were accepted as values at risk. Of all patients, 15.3% had NRS-2002 ≥ 3. Breast cancer was the most prevalent cancer type (24.5%) with the lowest risk of nutrition (4.9%, p < 0.001). Nutritional risk was significantly higher in patients with gastrointestinal cancer, head and neck cancer, and lung cancer (p < 0.005) and in patients with stage IV disease (p < 0.001). High anxiety levels (CAS ≥ 5) were significantly related to voluntary avoidance and clinical postponement of hospital visits due to the pandemic (p < 0.001), while clinical postponement was particularly frequent among patients with NRS-2002 < 3 (p = 0.0021). Fear and anxiety in cancer patients with COVID-19 cause hesitations in visiting hospitals, leading to disrupted primary and nutritional treatments. Thus, nutritional monitoring and treatment monitoring of cancer patients are crucial during and after radiotherapy.
- 6 July 2022
- Published by Taylor & Francis in Nutrition and Cancer
- Vol. 74 (10) , 1-10
Evaluation of Nutritional Status and Anxiety Levels in Patients Applying to the Radiation Oncology Outpatient Clinic during the COVID-19 Pandemic: Turkish Society for Radiation Oncology Group Study (TROD 12:02)
Cancer patients often face malnutrition, which negatively affects their response to cancer treatment. This study aims to analyze the effects of the COVID-19 pandemic on nutritional status and anxiety in cancer patients with different types and stages of cancer. This is a cross-sectional cohort study that includes 1,252 patients with varying cancer types from 17 radiation oncology centers. The nutritional risk scores (NRS-2002) and coronavirus anxiety scale (CAS) scores of all patients were measured. NRS-2002 ≥ 3 and CAS ≥ 5 were accepted as values at risk. Of all patients, 15.3% had NRS-2002 ≥ 3. Breast cancer was the most prevalent cancer type (24.5%) with the lowest risk of nutrition (4.9%, p < 0.001). Nutritional risk was significantly higher in patients with gastrointestinal cancer, head and neck cancer, and lung cancer (p < 0.005) and in patients with stage IV disease (p < 0.001). High anxiety levels (CAS ≥ 5) were significantly related to voluntary avoidance and clinical postponement of hospital visits due to the pandemic (p < 0.001), while clinical postponement was particularly frequent among patients with NRS-2002 < 3 (p = 0.0021). Fear and anxiety in cancer patients with COVID-19 cause hesitations in visiting hospitals, leading to disrupted primary and nutritional treatments. Thus, nutritional monitoring and treatment monitoring of cancer patients are crucial during and after radiotherapy.
- Open Access
- 29 June 2021
- Published by Scientific Archives
- Vol. 2 (1)
Radical Radiotherapy of Locally Advanced Cervix Uteri Carcinoma
- 29 June 2021
- Published by Scientific Archives
- Vol. 2 (1)
Open AccessRadical Radiotherapy of Locally Advanced Cervix Uteri Carcinoma